USPUSP-NF
This is a preview of
USP-NF/PF content.
Subscriber?
Access here!
Not a subscriber?
Learn more!
Cyclobenzaprine Hydrochloride Extended-Release Capsules

BRIEFING

 Cyclobenzaprine Hydrochloride Extended-Release Capsules. This proposal is based on the version of the monograph official as of May 1, 2020. The following changes are being proposed:

  1. Replace the IR spectral agreement test in Identification A with a test based on UV spectral agreement using the proposed Assay to eliminate the use of methylene chloride.

  2. Revise the Assay as follows:

    • Revise the Detector in the Chromatographic system to support the proposed Identification A.

    • Update the Chromatographic system to include Run time.

  3. Revise the test for Organic Impurities as follows:

    • Add a table and update the Note in the System suitability section to present relative retention times as an aid in peak assignment.

    • Revise Table 3 to list only the limits for any unspecified degradation product and total degradation products.

    • In the Acceptance criteria, add a reference to User-Determined Reporting Thresholds 〈477〉 for user flexibility.

    • Update the cyproheptadine related compound B name to dibenzocycloheptenone.

  4. Update the USP Reference Standards section to be consistent with current chemical information.

 Additionally, minor editorial changes have been made to update the monograph to current USP style.

 (SM4: G. Daddala)

 Case ID—SUB-2202

This is a preview of
USP-NF/PF content.
Subscriber?
Access here!
Not a subscriber?
Learn more!